Johnson & Johnson (JNJ) Total Liabilities (2009 - 2026)
Johnson & Johnson (JNJ) posted Total Liabilities of $119.7 billion for Q1 2026, up 1.74% sequentially from $117.7 billion in Q4 2025, and up 3.59% YoY from $115.6 billion in Q1 2025.
Johnson & Johnson (JNJ) Total Liabilities (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Total Liabilities data on file, last reported at $119.7 billion in Q1 2026.
- Quarterly Total Liabilities rose 3.59% year-over-year to $119.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.7 billion (up 3.59% YoY) and the FY2025 annual result came in at $117.7 billion, up 8.33% from the prior year.
- Total Liabilities grew to $119.7 billion in Q1 2026 per JNJ's latest filing, from $117.7 billion in the prior quarter.
- The five-year high for Total Liabilities was $125.1 billion in Q2 2023, with the low at $94.8 billion in Q4 2023.
- Average Total Liabilities over 5 years is $109.3 billion, with a median of $109.1 billion recorded in 2024.
- Year-over-year, Total Liabilities climbed 20.7% in 2023 and fell 18.51% in 2024.
- Johnson & Johnson's Total Liabilities stood at $100.5 billion in 2022, then retreated by 1.73% to $98.8 billion in 2023, then gained by 9.95% to $108.6 billion in 2024, then gained by 8.33% to $117.7 billion in 2025, then climbed by 1.74% to $119.7 billion in 2026.
- Business Quant data shows JNJ's Total Liabilities at $119.7 billion in Q1 2026, $117.7 billion in Q4 2025, and $113.5 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 85.38 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.71 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 143.12 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -66.63 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 82.81 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 83.31 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 32.76 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 117.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 10.83 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 119.71 Bn |
| Dec 28, 2025 | 117.67 Bn |
| Sep 28, 2025 | 113.54 Bn |
| Jun 29, 2025 | 114.92 Bn |
| Mar 30, 2025 | 115.56 Bn |
| Dec 29, 2024 | 108.61 Bn |
| Sep 29, 2024 | 108.13 Bn |
| Jun 30, 2024 | 109.55 Bn |
| Mar 31, 2024 | 101.95 Bn |
| Dec 31, 2023 | 98.78 Bn |
| Oct 1, 2023 | 94.83 Bn |
| Jul 2, 2023 | 115.28 Bn |
| Apr 2, 2023 | 125.10 Bn |
| Jan 1, 2023 | 110.57 Bn |
| Oct 2, 2022 | 100.53 Bn |
| Jul 3, 2022 | 101.37 Bn |
| Apr 3, 2022 | 103.65 Bn |
| Jan 2, 2022 | 108.00 Bn |
| Oct 3, 2021 | 108.96 Bn |
| Jul 4, 2021 | 106.86 Bn |